Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAetna panitumumab Coverage & Prior Auth | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0748

    Panitumumab (Vectibix)

    Customize your policy alerts

    Sign up for Aetna Policy 0748 alerts

    Get alerted when Policy 0748 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, precertification, and coverage criteria for panitumumab (Vectibix) in commercial Aetna medical plans, primarily addressing use in colorectal cancer and related testing requirements.

    Policy Summary
    PayerAetna
    PolicyPanitumumab (Vectibix) - coverage criteria
    Policy CodePolicy 0748
    Change TypeNo material clinical or coverage changes
    Effective DateMar 7, 2008
    Last ReviewFeb 5, 2024
    Next Review DateSep 26, 2024
    Key ActionObtain prior authorization and document RAS (KRAS/NRAS) wild-type status and clinical indication when requesting panitumumab.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 mg/kg q14drecommended metastatic colorectal cancer dose
    RAS wild-type requiredbiomarker requirement for efficacy/coverage
    Precertification requiredadministrative requirement for all participating providers
    89%patients reported dermatologic toxicities with panitumumab
    J9303HCPCS code for panitumumab (10 mg)

    Coverage Criteria for Panitumumab (Vectibix)

    Initial Approval — CRC

    Covered when ONE of the following two alternative pathways is met and member has not previously experienced clinical failure on cetuximab:

    Pathway 1: Member meets ALL: RAS (KRAS and NRAS) mutation status is negative (wild-type); and if tumor is BRAF V600E positive, panitumumab will be used in combination with encorafenib; and for colon cancer, tumor is left-sided only.

    Applies to unresectable/inoperable, advanced, or metastatic disease including appendiceal and anal adenocarcinoma

    Pathway 2: Member meets ALL: disease is KRAS G12C mutation positive; and the requested medication will be used in combination with sotorasib or adagrasib; and member previously received chemotherapy.

    Alternative biomarker-driven combination pathway

    Continuation of Therapy

    Covered when ALL of the following are met:

    Policy Summary
    PayerAetna
    PolicyPanitumumab (Vectibix) - coverage criteria
    Policy CodePolicy 0748
    Change TypeNo material clinical or coverage changes
    Effective DateMar 7, 2008
    Last ReviewFeb 5, 2024
    Next Review DateSep 26, 2024
    Key ActionObtain prior authorization and document RAS (KRAS/NRAS) wild-type status and clinical indication when requesting panitumumab.
    SourceLink
    On This Page
    Coverage Criteria for Panitumumab (Vectibix)Coding and BillingProvider Actions, Authorization, and DocumentationBackground and Evidence SummaryDefinitions and Biomarker TermsLine of Therapy ConsiderationsBiomarker Requirements for CoverageCovered and Investigational Regimens
    Continuation: Indication was previously approved under Section I; there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

    Requesting reauthorization

    Biomarker-driven coverage and tumor-specific evidence

    Evidence-supported use is generally limited to patients with RAS wild-type tumors and appropriate clinical indications.

    Biomarker requirement: Tumor must be KRAS/RAS wild-type for expected efficacy (supported by phase II/III analyses).KRAS/RAS wild-type

    Amado et al (2008) and Freeman et al (2008) showed confinement of benefit to wild-type KRAS tumors.

    Clinical scenarios with variable evidence: Panitumumab has been studied across mCRC, biliary tract cancer, small bowel/ampullary adenocarcinoma, anal carcinoma, bladder cancer, and breast cancer with mixed results; use should be aligned with evidence per tumor type and consideration of trial outcomes.

    Some trials showed benefit in KRAS wild-type biliary tract disease while others did not; SBA/AAC trial stopped for futility.

    Breast cancer (neoadjuvant, inflammatory / triple-negative subgroups)

    Evidence from phase II studies suggests possible benefit in biologically selected subgroups:

    Breast cancer neoadjuvant findings: Panitumumab in combination with neoadjuvant chemotherapy produced pathologic complete responses in subsets; triple-negative inflammatory breast cancer had the highest reported pCR (42%) in one trial; investigational biomarkers included pEGFR and COX-2.

    Further randomized data pending; consider enrollment in trials or biomarker-defined use.

    Cutaneous squamous cell carcinoma (locally advanced / unresectable)

    Phase II and case-series evidence:

    CSCC single-agent or combination use: Phase II single-agent panitumumab produced ORR ~31% with median PFS ~8 months; small series combining panitumumab with anti‑PD‑1 antibodies reported durable complete responses in a few heavily pretreated patients.

    Results are early and require validation; consider as option when local therapy is not suitable and after discussion of limited evidence.

    Esophageal / gastro-esophageal adenocarcinoma

    Randomized data do not support adding panitumumab to standard first-line chemotherapy in unselected populations:

    Gastro-esophageal adenocarcinoma evidence: Randomized trials (including REAL3 and other phase II/III studies) showed no OS benefit and increased GI/skin toxicities when panitumumab was added to first-line chemotherapy; use is not recommended in unselected advanced gastro-esophageal adenocarcinoma.

    Biomarker-selected use not established.

    Metastatic colorectal cancer (re-challenge / continuous EGFR therapy)

    Evidence on panitumumab beyond progression and continuous use is mixed and biomarker-dependent:

    mCRC re-challenge/continuous EGFR therapy: Trials assessing panitumumab re‑challenge or continuous use suggest potential benefit when circulating tumor DNA demonstrates RAS/BRAF wild-type; studies were small or prematurely closed and require further validation.RAS/BRAF wild-type by tissue or liquid biopsy

    Prior authorization should document molecular testing results and prior anti‑EGFR exposure.

    Head and neck squamous cell carcinoma (locally advanced)

    Randomized trials comparing addition or substitution of panitumumab in chemoradiotherapy regimens:

    HNSCC chemoradiotherapy findings: Phase II randomized trials showed no improvement in local‑regional control when panitumumab was added to standard chemoradiotherapy and in some comparisons panitumumab plus radiotherapy was inferior; increased mucosal, skin, and dysphagia toxicities were observed.ECOG 0-1 in trials

    Panitumumab cannot replace cisplatin with radiotherapy; role needs reassessment.

    Glioma / ErbB targeting

    Biologic rationale but limited clinical efficacy to date:

    Glioma context: ErbB family members are biologic targets in high‑grade glioma and EGFRvIII is associated with poor prognosis; anti‑ErbB approaches including panitumumab have entered trials but clinical efficacy is limited and remains investigational.

    Evidence primarily preclinical/early‑phase; not established for routine use.

    Coverage with criteria and restrictions

    Coverage recommendations and criteria inferred from the document:

    Colorectal cancer coverage: Panitumumab is appropriate only for tumors that are KRAS (or broader RAS) wild‑type; patients with KRAS mutations should not receive panitumumab due to lack of response and possible worse outcomes.KRAS wild-type required

    Explicit exclusion for KRAS‑mutant CRC in document.

    Head and neck cancer: Panitumumab monotherapy shows modest activity in platinum‑pretreated HNSCC (ORR ~6%, disease control ~51%); combinations replacing cisplatin in definitive chemoradiation did not demonstrate superior outcomes and cannot replace cisplatin; use as alternative when cisplatin is contraindicated requires clear justification.Documentation of prior platinum therapy and cisplatin ineligibility

    Supported by phase II/III trials.

    Non-small cell lung cancer: Addition of panitumumab to standard chemotherapy or chemoradiation did not show benefit and was associated with increased toxicity and mortality in some trials; not recommended outside clinical trials.

    Supported by randomized/phase II trial findings.

    Other solid tumors: Early‑phase trials report manageable toxicity but no clear survival benefit for many other tumor types; use is limited to clinical trials or requires payer case review.Trial‑level evidence only

    Derived from phase I/II data in pancreatic, sarcoma, and other cancers.

    Coverage for colorectal cancer (general)

    Covered when ALL of the following are met:

    Panitumumab coverage general: 1) Diagnosis of metastatic or unresectable colorectal cancer or other indication supported by evidence; 2) Tumor demonstrated to be RAS (KRAS/NRAS) wild‑type (no activating mutations); 3) Clinical use consistent with evidence‑based regimen (e.g., combined with FOLFOX or FOLFIRI as studied) or as monotherapy in appropriate refractory settings; 4) Provider documents prior therapies and rationale; 5) Dosing aligns with labeled/trial dosing (e.g., 6 mg/kg every 14 days).

    Derived from trial descriptions and prescribing information

    CAIRO5 subgroup coverage stance

    Restrictive consideration for first-line induction in initially unresectable CRC liver metastases:

    CAIRO5-guided use: 1) For right‑sided primary tumors or tumors with RAS or BRAFV600E mutations, FOLFOXIRI plus bevacizumab was preferred per CAIRO5; panitumumab‑containing regimens are not preferred. 2) For left‑sided, RAS/BRAFV600E wild‑type tumors, addition of panitumumab to FOLFOX or FOLFIRI showed no clinical benefit versus bevacizumab and was associated with more toxicity; panitumumab is therefore not preferred in this subgroup.

    Reflects CAIRO5 conclusions

    Administration and toxicity management

    Safety and administration conditions:

    Infusion and toxicity management: 1) Reduce infusion rate by 50% for mild infusion reactions; terminate infusion for severe reactions. 2) Withhold or discontinue panitumumab for severe or intolerable dermatologic toxicity; reduce dose for recurrent grade 3 dermatologic toxicity.

    Per labeling recommendations

    Aetna considers panitumumab (Vectibix) experimental and investigational for multiple non-colorectal cancer indications and for specific drug combinations where effectiveness has not been established. Examples of tumor types listed as experimental include ampullary adenocarcinoma, biliary tract cancer, bladder cancer, breast cancer, cutaneous squamous cell carcinoma, esophageal and gastric cancers, glioma, head and neck cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, penile cancer, and sarcoma.

    In addition, Aetna identifies certain investigational panitumumab constructs and combinations (for example, 212Pb-panitumumab, panitumumab-DOTA-111In radioimmunotherapy, and combinations with bevacizumab, erlotinib, or gefitinib) as experimental because clinical benefit has not been established and these uses are not supported by sufficient evidence.

    Panitumumab (Vectibix) should not be used in patients with known hypersensitivity to panitumumab or any component of the product. The safety and effectiveness of panitumumab in pediatric and adolescent patients have not been established and thus use in these populations is excluded unless evidence supports otherwise.

    The prescribing and coverage guidance also note contraindications or limitations related to pregnancy and breastfeeding without an appropriate documented risk–benefit discussion and require that labeled safety considerations be followed when evaluating requests for therapy.

    Randomized trial evidence does not support adding panitumumab to certain first-line gastro‑esophageal chemotherapy regimens in unselected patients. In particular, trial data showed that adding panitumumab to EOC/EOC‑type regimens did not improve overall survival and was associated with increased gastrointestinal and dermatologic toxicity; therefore, panitumumab added to first-line EOC/ECX/mFOLFOX6 chemotherapy for unselected advanced esophago‑gastric or gastro‑esophageal adenocarcinoma is not recommended and is considered excluded in this setting.

    More generally, Aetna designates the addition of panitumumab to standard first‑line chemotherapy for unselected gastro‑esophageal adenocarcinoma as not medically necessary based on the randomized data showing no benefit and higher toxicity.

    Use of panitumumab in colorectal cancer with KRAS (or broader RAS) activating mutations is explicitly excluded. Multiple sources in the policy state that patients with KRAS‑mutant tumors do not benefit from anti‑EGFR monoclonal antibodies and that provision of panitumumab in this population is contraindicated.

    The FDA‑labeled indication for panitumumab and the policy both require demonstration of RAS (KRAS and NRAS) wild‑type status for use in metastatic colorectal cancer; requests for therapy in tumors with documented activating KRAS mutations will be denied.

    Concurrent administration of panitumumab with certain other targeted agents is prohibited per the policy. Specifically, panitumumab may not be used in conjunction with cetuximab (Erbitux), erlotinib (Tarceva), gefitinib (Iressa), or bevacizumab (Avastin) because combinations with these agents are either not studied, ineffective, or associated with worse outcomes in clinical trials (for example, PACCE results with bevacizumab).

    Requests for coverage that propose concomitant use of panitumumab with these agents should be denied or require an investigational review as described in the policy.

    The policy reiterates that use of panitumumab in colorectal cancer patients with KRAS mutations is excluded because activating KRAS mutations are associated with lack of response to EGFR inhibitors and may be associated with worse outcomes.

    Prior to authorization for colorectal cancer, documentation of KRAS/RAS wild‑type status is required; panitumumab is not indicated for RAS‑mutant or unknown RAS status per the Vectibix limitation of use.

    The policy prohibits concurrent use of panitumumab with other EGFR‑directed monoclonal antibodies or with certain targeted agents. Specifically, panitumumab should not be used with cetuximab (Erbitux), erlotinib (Tarceva), gefitinib (Iressa), or bevacizumab (Avastin) because these combinations are either unestablished or contraindicated based on trial data.

    Providers requesting panitumumab in combination with any of these agents must provide supportive clinical trial evidence and obtain investigational review; absent compelling justification, such combinations are considered noncovered.

    This Clinical Policy Bulletin provides a summary of the plan’s medical necessity criteria for panitumumab and related administrative requirements, but it contains only a partial, general description of plan or program benefits and does not constitute a contract.

    Participating providers are responsible for clinical decision‑making and must follow plan procedures for prior authorization and documentation; the bulletin may be updated and plan‑specific provisions apply.

    Panitumumab (Vectibix) is indicated and covered only for patients with metastatic colorectal cancer whose tumors are RAS (KRAS and NRAS) wild‑type. The policy explicitly states that panitumumab is not indicated for patients with RAS‑mutant or unknown RAS status, consistent with the labeled limitation of use.

    For colorectal cancer indications, prior authorization must include documentation of the tumor’s RAS/KRAS wild‑type status to support coverage decisions; absence of this documentation or presence of activating RAS mutations precludes approval.

    Clinical trial and regulatory evidence show that tumors with activating KRAS mutations do not respond to panitumumab and therefore panitumumab use in this setting is considered inappropriate. Amado and others demonstrated confinement of benefit to KRAS/RAS wild‑type tumors.

    As a result, the policy requires molecular testing demonstrating absence of activating KRAS (and extended RAS) mutations before panitumumab is considered medically necessary for colorectal cancer.

    Randomized phase II/III trials in unselected metastatic gastro‑esophageal adenocarcinoma populations found no survival benefit and increased toxicity when panitumumab was added to standard first‑line chemotherapy. Therefore, panitumumab added to standard first‑line chemotherapy in unselected metastatic gastro‑esophageal adenocarcinoma is not medically necessary and will not meet coverage criteria.

    These findings support exclusion of panitumumab in this unselected first‑line gastric/gastro‑esophageal setting unless biomarker‑selected benefit is subsequently demonstrated.

    Multiple randomized and controlled trials in non‑small cell lung cancer and in combined chemoradiation settings did not demonstrate benefit from adding panitumumab and in some studies showed increased toxicity and higher mortality. As such, use of panitumumab in NSCLC (either combined with standard chemotherapy or as part of chemoradiation) is not medically necessary outside of clinical trials.

    Trial closures for futility and higher adverse event rates underscore that panitumumab should not be used routinely in NSCLC.

    In the CAIRO5 randomized study of first‑line induction regimens for initially unresectable colorectal cancer liver metastases, addition of panitumumab to FOLFOX or FOLFIRI in left‑sided, RAS/BRAFV600E wild‑type tumors did not improve outcomes versus bevacizumab and was associated with higher toxicity. Therefore, addition of panitumumab to FOLFOX or FOLFIRI for left‑sided, RAS/BRAFV600E wild‑type unresectable CRC liver metastases is not preferred and is not supported for routine use in place of bevacizumab.

    CAIRO5 subgroup findings favor bevacizumab‑containing regimens in many settings and indicate that panitumumab‑containing regimens had more adverse events in these comparisons.

    Related CPT and HCPCS codes are referenced under the coverage criteria and in the CODING section of the policy. Providers should refer to the CODING section for the full list of relevant procedure and drug billing codes (for example, CPT code 81275 for KRAS testing and HCPCS code J9303 for panitumumab billing).

    Accurate documentation of the indicated ICD‑10 diagnosis code consistent with policy criteria (for example, left‑sided colon malignancy codes when coverage criteria specify laterality) is required when submitting prior authorization requests.

    Coding and Billing

    Related CPT CodesCPT
    81275KRAS gene analysis; variants in exon 2 (eg, codons 12 and 13).
    81276additional variant(s) (eg, codon 61, codon 146).
    81311NRAS gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61).
    81404Molecular pathology procedure, Level 5.
    81210BRAF V600 variant analysis.
    88363Examination and selection of retrieved archival tissue(s) for molecular analysis.
    96365-96368Intravenous infusion, for therapy, prophylaxis, or diagnosis.
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular.
    96379Unlisted therapeutic intravenous or intra-arterial injection or infusion.
    96413-96417Chemotherapy administration, intravenous infusion technique.
    HCPCS / J-codesHCPCS
    J9303Injection, panitumumab, 10 mg.
    J9055Injection, cetuximab, 10 mg.
    J9190Injection, fluorouracil, 500 mg.
    J9206Injection, irinotecan, 20 mg.
    J9263Injection, oxaliplatin, 0.5 mg.
    J9045Injection, carboplatin, 50 mg.
    ICD-10 Diagnosis Codes (selected)ICD-10
    C18.0-C18.9Malignant neoplasm of colon [covered for left-sided tumors only].
    C19-C21.8Malignant neoplasm of rectosigmoid junction, rectum, anus and anal canal.
    C15.3-C15.9Malignant neoplasm of esophagus (listed as not covered for CPB indications).
    C16.0-C16.9Malignant neoplasm of stomach (listed as not covered for CPB indications).
    C44.02Squamous cell carcinoma of skin.
    C50.011-C50.929Malignant neoplasm of breast.
    Relevant HCPCS for drug billingHCPCS
    HCPCS: J9306Panitumumab injection (per 1 mg) (listed as example for panitumumab billing in prior auth guidance).
    inv-31: Infusion duration
    Infusion durationInfuse over 60 minutes for doses ≤1000 mg; 90 minutes for doses >1000 mg.
    RouteIntravenous (IV) infusion as per labeled administration.
    Dose thresholdDifferent infusion duration applies at total dose of 1000 mg (≤1000 mg = 60 min; >1000 mg = 90 min).
    inv-32: Panitumumab dosing (CAIRO5)
    CAIRO5 / trial dosing6 mg/kg IV every 14 days (used in CAIRO5 and standard mCRC dosing).
    Indication contextDosing schedule used for first-line induction in CAIRO5 for unresectable CRC liver metastases (combined with chemotherapy backbones).
    Administration noteAdministered as intravenous infusion; follow infusion duration guidance based on total dose (see infusion duration).
    RegimenIndicationCoverage
    Panitumumab 6 mg/kg IV every 14 days
    Metastatic colorectal cancer — as first‑line in combination with FOLFOX, or as monotherapy after progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens
    Covered with criteria (RAS [KRAS/NRAS] wild-type required; prior clinical failure on cetuximab disallows coverage; dosing per labeling: 6 mg/kg q14d)

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Precertification Required

    Precertification/authorization is required for panitumumab (Vectibix). Lack of precertification may result in denial. For precertification call (866) 752-7021 or fax (888) 267-3277; Statement of Medical Necessity (SMN) forms are available via Aetna Specialty Pharmacy Precertification.

    • Precertification required for all Aetna participating providers and members in applicable plan designs.
    • Failure to precertify may lead to claim denial.
    Note

    Prior Authorization May Be Required

    Prior authorization may be required per plan provisions; providers should consult the Clinical Policy Bulletin and plan-specific rules when submitting requests.

    • Authorization determinations follow plan benefits and the Clinical Policy Bulletin.
    • Providers must verify plan-specific prior authorization requirements before treatment.
    Documentation Required

    Prior Authorization and Required Documentation

    Prior authorization requests must include documentation of tumor diagnosis, line of therapy, prior therapies (including platinum exposure for HNSCC when applicable), and relevant biomarker testing. CPT codes for molecular testing (e.g., KRAS, NRAS, BRAF) should be documented on requests.

    • Include tumor type, stage, and line of therapy.
    • Document prior systemic therapies and dates (e.g., prior platinum for HNSCC).
    • Attach molecular testing reports and relevant CPT codes (e.g., 81275, 81276, 81311, 81210, 81404, 88363).
    Denial Risk

    KRAS/RAS Wild-Type Documentation Required; Mutation Exclusion

    Requests for panitumumab for colorectal cancer must include evidence of RAS (KRAS and NRAS) wild-type status (or documented alternative authorized molecular scenario per criteria). Use in tumors with activating KRAS/RAS mutations lacks efficacy and may be denied.

    • KRAS/RAS wild-type verification is required to support panitumumab efficacy in mCRC.
    • Requests for patients with KRAS or other RAS activating mutations should be denied unless meeting an explicit authorized exception in the policy.
    • If BRAF V600E is present, documentation that panitumumab will be used in combination with encorafenib is required per criteria.
    Denial Risk

    KRAS Mutation Exclusion and Concomitant Therapy Restrictions

    Panitumumab should not be used in patients with KRAS-mutated colorectal cancer; such use is contraindicated due to lack of response and possible worse outcomes. Panitumumab may not be used in conjunction with cetuximab, erlotinib, gefitinib, or bevacizumab based on trial data.

    • Use in colorectal cancer patients with KRAS mutations will be denied.
    • Concurrent use with cetuximab (Erbitux), erlotinib (Tarceva), gefitinib (Iressa), or bevacizumab (Avastin) is not allowed.
    Note

    REAL3/PACCE and Other Negative Trial Implications

    Clinical trial data (e.g., PACCE, REAL3, EOC studies) have shown lack of benefit or harm when panitumumab (or EGFR antibodies) were added to certain chemotherapy regimens in unselected populations; cite these outcomes when denying requests lacking appropriate biomarker selection.

    • PACCE and REAL3/REAL3-like trials showed decreased PFS or no OS benefit and increased toxicity when EGFR antibodies were added in unselected populations.
    • Addition of panitumumab to EOC chemotherapy did not improve OS and increased grade 3–4 toxicities; therefore not recommended for unselected gastro-esophageal adenocarcinoma.
    • CAIRO5 results: in left-sided, RAS/BRAFV600E wild-type tumors, panitumumab added to FOLFOX/FOLFIRI showed no clinical benefit over bevacizumab and increased toxicity in some groups.
    Documentation Required

    Prior Anti‑EGFR Exposure, Re‑challenge, and Use After Cetuximab Intolerance

    Re-challenge or use after prior anti-EGFR exposure requires careful documentation. Prior clinical failure on cetuximab is a contraindication to panitumumab per the policy; however, limited case reports suggest panitumumab may be used after cetuximab hypersensitivity/intolerance in select cases under strict observation and with appropriate authorization.

    • Requests should state whether the member previously experienced clinical failure on cetuximab — prior clinical failure disallows panitumumab.
    • For cetuximab hypersensitivity/intolerance (not clinical failure), include detailed clinical rationale and prior reaction documentation; single-patient reports exist but are not definitive evidence of safety or efficacy.
    • Re-challenge strategies and liquid biopsy (ctDNA) results that show RAS wild-type status may be considered in authorization decisions; provide serial molecular testing results when applicable.
    Documentation Required

    Molecular Testing and Tumor Location Documentation

    When applicable, provide molecular testing documentation including tumor RAS and BRAF V600E status and primary tumor laterality (left vs right) for colorectal cancer, and whether testing was performed on tissue or liquid biopsy (circulating tumor DNA).

    • Specify testing method and date (tissue vs liquid biopsy) and include laboratory reports.
    • Document primary tumor laterality (left-sided vs right-sided) for colon cancer, as this affects regimen selection and authorization.
    • If liquid biopsy is used to guide re-challenge or later-line therapy, include serial ctDNA results showing RAS/BRAF status.
    Documentation Required

    Required Clinical Documentation

    Clinical documentation should include diagnosis, tumor type and stage, prior therapies (with dates), line of therapy, biomarker results, and clinical rationale for panitumumab use in context of available evidence and guideline-supported sequencing (for example CAIRO5 subgroup considerations).

    • Include complete prior therapy history (agents, dates, responses) and objective evidence of progression or intolerance when relevant.
    • Provide clinical rationale referencing guideline- or trial-based sequencing (e.g., preferred regimens vary by mutation status and sidedness in CAIRO5).
    • Attach pathology and molecular test reports to the authorization request.
    Note

    Provider Responsibility and Policy Nature

    Participating providers are independent contractors and are solely responsible for medical advice and treatment. The Clinical Policy Bulletin is a partial description of plan benefits, may be updated, and does not constitute a contract.

    • Policy contents may change; providers should confirm current criteria and plan provisions.
    • Clinical policy guidance does not replace professional judgment — treating providers remain responsible for patient care.

    Background and Evidence Summary

    Panitumumab (Vectibix) is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and is indicated for treatment of metastatic colorectal cancer that is RAS (KRAS and NRAS) wild‑type.

    The FDA‑approved dosing regimen referenced in the policy and trials is 6 mg/kg IV every 14 days, and the policy’s coverage criteria align with this labeled/trial dosing for first‑line combination with FOLFOX or as monotherapy in later‑line settings after progression on prior chemotherapies.

    Definitions and Biomarker Terms

    inv-59: RAS wild-type
    DefinitionRAS wild-type is defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test.
    Regulatory requirementRequired for Vectibix (panitumumab) FDA indication in metastatic colorectal cancer.
    Clinical implicationRAS wild-type status is associated with treatment benefit and is used to select patients for panitumumab therapy.
    inv-60: KRAS/RAS wild-type
    DefinitionKRAS/RAS wild-type: tumor genomic status without activating KRAS (and extended RAS) mutations.
    Predictive roleAssociated with response to anti-EGFR therapy such as panitumumab; studies show lack of response in KRAS-mutant tumors.
    TestingKRAS/RAS assessment should be performed on tumor tissue (or validated liquid biopsy) to inform therapy selection.
    inv-61: EGFR / ErbB family
    DefinitionEGFR (ErbB1/HER1) is a receptor tyrosine kinase in the ErbB family (ErbB1–4) that signals for cell proliferation and survival.
    Therapeutic targetMonoclonal antibodies (e.g., panitumumab) target EGFR to inhibit downstream proliferative signaling.
    Biologic contextEGFRvIII is a constitutively active EGFR mutant associated with poor prognosis in glioblastoma; anti-ErbB approaches focus mainly on EGFR.
    inv-62: KRAS wild-type
    DefinitionKRAS wild-type: tumors without activating KRAS mutations.
    Coverage implicationKRAS wild-type is required for efficacy of panitumumab in colorectal cancer per clinical trial evidence and policy wording.
    Exclusion notePatients with KRAS mutations should not receive panitumumab due to lack of response and possible worse outcomes.
    inv-63: ORR
    DefinitionObjective response rate (ORR) is the proportion of patients with tumor size reduction of a predefined amount per RECIST criteria.
    Use in trialsORR is a primary or secondary endpoint reported in phase II trials of panitumumab across tumor types (example: ORR 31% in CSCC phase II).
    Assessment standardMeasured according to RECIST version used in individual trials (e.g., RECIST v1.1).
    inv-64: RAS/KRAS wild-type
    DefinitionRAS/KRAS wild-type: tumors that do not harbor activating mutations in KRAS or NRAS genes.
    Therapeutic requirementRequired for expected panitumumab efficacy in colorectal cancer; used as a selection biomarker in trials and for coverage determinations.
    Testing modalitiesWild-type status may be determined by tumor tissue testing or validated circulating tumor DNA assays when applicable.
    inv-65: FOLFOX/FOLFIRI/FOLFOXIRI
    FOLFOX compositionFOLFOX includes oxaliplatin plus folinic acid and fluorouracil (standard backbone used in CAIRO5).
    FOLFIRI compositionFOLFIRI includes irinotecan plus folinic acid and fluorouracil (standard backbone used in CAIRO5).
    FOLFOXIRI compositionFOLFOXIRI combines irinotecan, oxaliplatin, folinic acid, and fluorouracil (used as an alternative induction regimen in CAIRO5).
    inv-66: Clinical Policy Bulletin
    PurposeClinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and do not constitute offers of coverage or medical advice.
    ScopeBulletins summarize coverage criteria, prior authorization requirements, and clinical evidence used to guide benefit administration.
    Update cyclePolicy history includes last review and next review dates noted in the bulletin (last review: 02/05/2024).

    Line of Therapy Considerations

    first-line | second-line

    Line of therapy: Panitumumab may be used as first‑line therapy in combination with FOLFOX, or as monotherapy after progression following fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑containing chemotherapy (FDA‑approved indications).

    See prescribing information for labeled indications and limits.

    first-line

    First-line (biliary tract): Panitumumab was studied as part of first‑line combination chemotherapy for KRAS wild‑type unresectable/metastatic biliary tract cancer in phase II trials; selection required KRAS wild‑type status.KRAS wild-type

    Evidence from Jensen and Hezel phase II trials.

    second-line

    Second-line / salvage: Panitumumab has been used as monotherapy in later‑line settings for mCRC after prior chemotherapies; small case series describe use after cetuximab intolerance with variable outcomes.

    Use following cetuximab intolerance described in small case series; prior clinical failure on cetuximab is disallowed for coverage.

    second-line | re-challenge

    Second-line | re-challenge: Consider panitumumab beyond progression or continuous EGFR therapy only when circulating tumor DNA or tissue testing shows RAS/BRAF wild‑type and prior response to EGFR therapy is documented; evidence is limited and further validation is required.RAS/BRAF wild-type by tissue or liquid biopsy

    BEYOND and other small studies investigated P‑FOLFIRI beyond progression.

    first-line

    First-line (gastro-esophageal negative trials): Randomized trials do not support adding panitumumab to standard first‑line chemotherapy in unselected gastro‑esophageal adenocarcinoma; increased toxicity and decreased OS were observed in REAL3 and related studies.

    Not recommended in unselected first‑line use.

    second-line | alternative for cisplatin-ineligible definitive therapy

    Second-line | cisplatin-ineligible alternative: For locally advanced head and neck cancer in patients ineligible for high‑dose cisplatin, panitumumab combinations (e.g., induction paclitaxel plus panitumumab followed by bio‑RT) have been studied but showed higher toxicity; use as an alternative requires documentation of cisplatin ineligibility and careful risk‑benefit consideration.Documentation of cisplatin ineligibility and prior platinum status

    Evidence from single‑arm phase II trials; safety signals present.

    first-line investigational/combined-modality

    First-line investigational/combined-modality: Panitumumab has been evaluated in combined‑modality regimens (e.g., with chemoradiation) in pancreatic and other cancers in early‑phase trials that reported high toxicity and limited efficacy; routine use is investigational.

    Phase I/II trials showed unacceptable toxicity in some regimens.

    first-line

    First-line (CAIRO5 context): CAIRO5 evaluated panitumumab combined with FOLFOX or FOLFIRI for induction in unresectable CRC liver metastases; results do not favor panitumumab over bevacizumab in left‑sided RAS/BRAFV600E wild‑type tumors and showed more toxicity.

    Not preferred versus bevacizumab in left‑sided RAS/BRAF WT subgroup.

    salvage

    Salvage: Panitumumab monotherapy has documented activity in chemotherapy‑refractory metastatic colorectal cancer in RAS wild‑type patients and is an option in salvage settings per earlier trials and prescribing information.RAS wild-type required

    Supported by phase III and earlier trials (Amado et al., prescribing information).

    Biomarker Requirements for Coverage

    inv-76: RAS (KRAS and NRAS)
    Required biomarker statusRAS (KRAS and NRAS) must be negative (wild-type) for panitumumab coverage/efficacy in mCRC.
    BRAF testingBRAF V600E status is relevant; if positive, panitumumab should be combined with encorafenib per initial approval pathway.
    Testing documentationKRAS/RAS wild-type verification is expected prior to initiation and may be required for prior authorization and coverage decisions.
    inv-77: BRAF V600E
    MutationBRAF V600E: presence of V600E mutation noted; when positive, panitumumab should be used in combination with encorafenib (Braftovi) per approval pathway.
    Role in CAIRO5BRAF V600E mutation status was a stratification factor in CAIRO5 and affected subgroup allocation.
    Clinical implicationBRAF V600E positivity guides combination therapy choices rather than panitumumab monotherapy.
    inv-78: KRAS G12C
    MutationKRAS G12C: presence of G12C mutation identified as an alternative pathway; panitumumab to be used in combination with KRAS G12C inhibitors (sotorasib or adagrasib) per policy pathway.
    Coverage pathwayApplicable when disease is KRAS G12C mutation positive and patient has prior chemotherapy exposure.
    Clinical noteThis represents a biomarker-driven combination pathway rather than standard panitumumab monotherapy.
    inv-79: KRAS (and extended RAS)
    RequirementKRAS (and extended RAS) must be wild-type for expected benefit from panitumumab in mCRC.
    EvidenceMultiple studies (Amado et al., Freeman et al.) demonstrated that activating KRAS mutations predict lack of response.
    Coverage implicationRequests for panitumumab in KRAS-mutant CRC will be denied per policy statements.
    inv-80: RAS (KRAS/NRAS), BRAF
    Testing modalitiesRAS (KRAS/NRAS) and BRAF wild-type status may be determined by tissue testing or circulating tumor DNA (liquid biopsy) for selection in re-challenge/continuous use contexts.
    Clinical useLiquid biopsy (ctDNA) has been used in trials to select patients for panitumumab re-challenge beyond progression.
    DocumentationPrior authorization should include molecular testing results (tissue or ctDNA) when considering re-challenge strategies.
    inv-81: pEGFR, COX-2
    Exploratory biomarkerspEGFR and COX-2 were identified as potential predictors of pathologic complete response (pCR) in inflammatory triple-negative breast cancer trials involving panitumumab.
    Evidence statusThese biomarkers are investigational and require validation in randomized studies before routine use for selection.
    ContextFindings arose from neoadjuvant trials reporting higher pCR rates in biomarker-selected subsets.
    inv-82: KRAS
    RequirementKRAS must be wild-type (no activating KRAS mutations) for panitumumab use in colorectal cancer.
    Policy consequencePolicy explicitly states KRAS-mutant CRC patients should not receive panitumumab due to lack of response and possible worse outcomes.
    Testing expectationKRAS testing and documentation should be provided for authorization and treatment decisions.
    inv-83: EGFR copy number gain (CNG)
    Exploratory findingEGFR copy number gain (CNG) was associated with longer progression-free survival in a phase II HNSCC series (exploratory observation).
    Clinical implicationEGFR CNG is investigational as a predictive biomarker and not required for routine panitumumab use.
    Evidence statusObservation derived from small phase II trial; requires validation in larger studies.
    inv-84: KRAS (and broader RAS)
    SummaryKRAS and broader RAS must be wild-type (no activating mutations) for expected panitumumab benefit in colorectal cancer.
    Coverage implicationRequests for panitumumab in RAS-mutant colorectal cancer are contraindicated and will be denied.
    TestingVerify RAS wild-type status by tissue or validated liquid biopsy prior to initiating therapy when required by policy.
    inv-85: BRAFV600E
    Role in CAIRO5BRAFV600E mutation status was used for subgroup allocation in CAIRO5 (influencing treatment assignment and analyses).
    Clinical implicationBRAF mutation influenced preferred regimens in CAIRO5; BRAFV600E tumors were excluded from some panitumumab comparisons in subgroup analyses.
    DocumentationBRAF status should be provided when requesting panitumumab for unresectable CRC liver metastases as per CAIRO5 considerations.

    Covered and Investigational Regimens

    RegimenIndicationCoverage
    Panitumumab 6 mg/kg IV every 14 days
    Metastatic colorectal cancer — first‑line with FOLFOX or as monotherapy after progression on standard chemotherapies
    Covered with criteria (requires documented RAS [KRAS/NRAS] wild-type status; limitation of use: not indicated for RAS‑mutant or unknown RAS status)
    RegimenAgents/ContextCoverage
    Panitumumab in combination
    Bevacizumab, erlotinib, or gefitinib (any combination) — combinations not established
    Experimental / investigational (effectiveness not established)
    RegimenIndicationCoverage
    Panitumumab combined with gemcitabine + oxaliplatin (± capecitabine) — panitumumab 6 mg/kg q2w used in trials
    KRAS wild-type biliary tract cancer — first‑line trial regimens
    Mixed / supportive for further study; marker‑driven (KRAS wild‑type) selection used in trials — considered investigational outside trial or without KRAS WT documentation
    RegimenIndicationCoverage
    Panitumumab combined with anthracycline‑taxane–based neoadjuvant chemotherapy (e.g., panitumumab + FEC100 → docetaxel; panitumumab + nab‑paclitaxel + carboplatin → FEC)
    Neoadjuvant therapy in breast cancer — triple‑negative and inflammatory breast cancer (TNBC/IBC) evaluated in phase II trials
    Investigational / experimental — signal of pCR in selected subgroups (e.g., TN IBC) but not established for routine coverage
    RegimenIndicationCoverage
    Panitumumab added to MMC‑5‑FU–based chemoradiation (as studied: panitumumab 3 mg/kg with MMC/5‑FU and IMRT)
    Locally advanced anal squamous cell carcinoma (combined with definitive CRT) — phase II trial
    Not covered / not recommended — trial failed to meet expected CR rate and showed poor tolerance
    RegimenIndicationCoverage
    Panitumumab + FEC100 → docetaxel; or panitumumab + nab‑paclitaxel + carboplatin → FEC (neoadjuvant schemas used in IBC trials)
    Inflammatory breast cancer / operable TNBC evaluated in neoadjuvant studies (pCR observed in subsets)
    Investigational — promising pCR in subsets but requires randomized validation; considered experimental for routine coverage
    RegimenIndicationCoverage
    Panitumumab 6 mg/kg IV every 2 weeks (single‑agent) as used in phase II CSCC trial
    Advanced cutaneous squamous cell carcinoma not suitable for local therapy — phase II population
    Experimental / limited evidence — single‑agent activity observed (ORR ~31%) in phase II; consider investigational or case‑by‑case with documentation
    RegimenIndicationCoverage
    Panitumumab combined with FOLFIRI (continuous use or re‑challenge strategies)
    Metastatic colorectal cancer — re‑challenge or beyond‑progression strategies selected by circulating tumor DNA (RAS/BRAF WT)
    Mixed — potential benefit when selected by circulating tumor DNA (RAS/BRAF WT) but requires further validation; prior authorization should document molecular testing
    RegimenIndicationCoverage
    Panitumumab added to EOC/ECX/mFOLFOX6 (e.g., panitumumab 6–9 mg/kg with various chemo backbones)
    First‑line treatment for unselected advanced gastro‑esophageal adenocarcinoma
    Not covered / not medically necessary — randomized trials showed no benefit and increased toxicity (REAL3 and other studies)
    RegimenIndicationCoverage
    Panitumumab 9 mg/kg IV every 2–3 weeks in combination with radiotherapy ± chemotherapy (as studied in various trials)
    Used with altered fractionation radiotherapy or with paclitaxel induction and bio‑RT in head & neck or other settings
    Mixed / investigational — studied but not established as superior; safety concerns and increased toxicity reported in some trials
    RegimenIndicationCoverage
    Panitumumab combined with pemetrexed/cisplatin or carboplatin/paclitaxel, or used to replace cisplatin in definitive chemoradiation regimens
    Non‑small cell lung cancer or as cisplatin replacement in HNSCC definitive CRT (evaluated in trials)
    Not covered / not recommended — trials showed lack of benefit and/or increased toxicity; replacement of cisplatin not established
    RegimenIndicationCoverage
    Radiolabeled panitumumab constructs (e.g., panitumumab‑DOTA‑111In) under preclinical/early‑phase investigation
    Theranostic applications and preclinical models for triple‑negative breast cancer and other targets
    Experimental / investigational — preclinical and early‑phase evidence only; not covered for routine use
    RegimenIndicationCoverage
    Panitumumab 6 mg/kg IV every 14 days combined with FOLFOX or FOLFIRI as evaluated in CAIRO5
    First‑line induction for initially unresectable colorectal cancer liver metastases (CAIRO5 subgroups) — used in left‑sided, RAS/BRAFV600E WT arm comparisons
    Mixed / not preferred in specific subgroup — CAIRO5 showed no benefit and more toxicity versus bevacizumab in left‑sided RAS/BRAFV600E WT tumors; panitumumab not preferred in that subgroup (coverage contingent on subgroup and documentation)
    RegimenIndicationCoverage
    Triplet: ganitumab + everolimus + panitumumab (phase I dose‑escalation) or doublet ganitumab + everolimus
    Advanced sarcoma / refractory solid tumors evaluated in phase I trial
    Triplet associated with unacceptable toxicity (not covered); doublet showed activity but remains investigational
    GuidanceActionCoverage implication
    Infusion reaction management
    Reduce infusion rate by 50% for mild reactions; terminate infusion for severe infusion reactions
    Per labeling — informs withholding/termination decisions; see authorization documentation for discontinuation criteria
    RegimenIndication / ContextCoverage
    Panitumumab (Vectibix) — anti‑EGFR monoclonal antibody
    Referenced in literature and reviews on anti‑EGFR therapy for advanced colorectal cancer
    Informational / referenced — supports contextual discussion of anti‑EGFR class; coverage determined by indication‑specific criteria